U.S. Government Engages Dx Firms For Rapid, Field-Based Ebola Test
This article was originally published in The Gray Sheet
Executive Summary
Multiple companies are receiving funding or are in discussions with federal agencies about development of rapid assays for Ebola that can be used by patients and health care workers in the field, a top official at the National Institute of Allergy and Infectious Diseases told "The Gray Sheet."
You may also be interested in...
Ebola Response Funds From Congress, Gates Group Could Hasten Rapid Test Development
The House FY 2015 federal spending continuing resolution would direct HHS and CDC to spend $88 million to deliver Ebola countermeasures, while Gates Foundation gives $50 million to the cause.
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.